1) TKI
小分子酪氨酸激酶抑制剂
1.
Drugs targeting EGFR receptors have already been successfully implicated in clinic and all belong to two categories:monoclonal antibodies and tyrosine kinase inhibitors(TKIs).
靶向EGFR家族的抗肿瘤药物可以分为单克隆抗体和小分子酪氨酸激酶抑制剂两大类。
2) Receptor tyrosine kinase inhibitor
受体酪氨酸激酶抑制剂
1.
Objective To explore the protective role of the receptor tyrosine kinase inhibitor in chondrocyte in vitro.
目的通过对体外培养软骨细胞的实验研究,探寻受体酪氨酸激酶抑制剂对软骨细胞在细胞分子水平的影响及其可能机制。
3) Tyrosine kinase inhibitors
酪氨酸激酶抑制剂
1.
Progress of epidermal growth factor receptor and tyrosine kinase inhibitors in the cancer therapy;
表皮生长因子受体与酪氨酸激酶抑制剂在肿瘤防治中的应用进展
2.
Recently, several approaches such as monoclonal an tibodies, bispecific antibodies, low molecular weight tyrosine kinase inhibitors and gene therapy targeting the EGFR family of receptors for anti-tumor therapy have been developed, some of which are currently undergoing clinical trials.
近年来 ,许多以此为靶点的新的抗肿瘤药物和治疗方法陆续被开发 ,主要有单克隆抗体、双特异性抗体、小分子酪氨酸激酶抑制剂和基因治疗等。
4) Janus kinase 3 inhibitor
酪氨酸激酶Jak3抑制剂
5) epidermal growth factor receptor tyrosine kinase inhibitor
EGFR酪氨酸激酶抑制剂
1.
Erlotinib,an epidermal growth factor receptor tyrosine kinase inhibitor;
小分子EGFR酪氨酸激酶抑制剂盐酸埃罗替尼
6) tyrosine kinase inhibitor
酪氨酸蛋白激酶抑制剂
1.
Objective To assess the effect of tyrosine kinase inhibitor (2,5-MC) on the inhibition of in-stent inti-mal hyperplasia.
目的评估酪氨酸蛋白激酶抑制剂2,5-MC抑制支架植入术后内膜增殖的效果。
补充资料：小分子
小分子
相对分子质量一般小于500，为简单的单体物质。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条